With the application of high-throughput approaches from genomics, combinatorial chemistry, and screening, the pharmaceutical industry is now faced with an overabundance of potential leads rather than a shortage of initial hits. Technologies are emerging to help better identify the most promising leads, but it is critical that these technologies be able to attain validation and acceptance by regulatory agencies as well as have the ability to run in parallel with other techniques in order to accelerate lead selection decisions. This conference will provide a forum for problem solving in this arena.